Ascendis Pharma A/S (ASND) AI Stock Analysis

Ascendis Pharma A/S is a Denmark-based biopharmaceutical company focused on addressing unmet medical needs through innovative therapies. The company's lead commercial product is SKYTROFA, developed for individuals with growth hormone deficiency. Its clinical pipeline includes TransCon Growth Hormone for pediatric and adult growth hormone deficiency and Turner syndrome, TransCon Parathyroid Hormone for adults with hypoparathyroidism, and TransCon C-type natriuretic peptide targeting achondroplasia. In addition, Ascendis Pharma is advancing oncology candidates including TransCon toll-like receptors 7/8 agonist for intratumoral delivery and TransCon IL-2 β/γ for systemic delivery across medical domains.

Ascendis Pharma demonstrated substantial top-line expansion, increasing revenue from $7.8M in FY2021 to $51.2M in FY2022, $266.7M in FY2023, $363.6M in FY2024, and $691.7M in FY2025, reflecting a 5-year revenue CAGR of 150.9%. While net income was -$219.0M in FY2025, operating cash flow turned positive at $51.8M alongside free cash flow of $43.6M. In the trailing twelve months, revenue reached $1.05B with net EPS of $13.05, a profit margin of 70.9%, and an operating margin of 65.0%. For the latest quarter ending June 30, 2026, quarterly revenue grew 114.7% year-over-year.

As of June 30, 2026, Ascendis Pharma reported cash and short-term investments of $811.9M against total debt of $449.9M, resulting in net cash of $362.0M. The company maintains solid liquidity with a current ratio of 2.99 and a debt-to-equity ratio of 0.31 on total assets of $2.29B and shareholders' equity of $1.44B. In FY2025, operating cash flow was $51.8M, supporting capital expenditures of $8.2M and share buybacks of $16.7M.

At a market cap of $14.82B and enterprise value of $14.26B, Ascendis Pharma trades at a trailing P/E of 17.3x, compared to 24.6x for the median of its US-listed Healthcare peers. Its forward P/E stands at 19.8x versus the peer median of 17.3x, while its price-to-sales multiple is 14.2x against the peer median of 4.1x, and EV/EBITDA is 65.4x versus 12.0x. Over the past year, the stock returned 8.8%, trailing the S&P 500 return of 16.8%, and gained 40.8% over five years compared to 83.0% for the S&P 500.

Wall Street coverage includes 16 Strong Buy ratings and 5 Buy ratings, with zero Hold, Sell, or Strong Sell recommendations. The mean price target of $306.87 represents an upside of 36.2% from the last close of $225.25. For the current fiscal year ending December 31, 2026, analysts project revenue of $1.37B and EPS of $12.79, reflecting EPS growth of 217.5%. Ascendis Pharma posted 1 EPS beat over the last 4 quarters, and its next earnings date is scheduled for November 11, 2026.

This page is an AI-written research summary of Ascendis Pharma A/S (ASND). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: ASND income statement, ASND balance sheet, ASND key metrics, ASND analyst forecast, ASND chart. See the ASND stock overview for the latest quote and news.